Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Iterum Therapeutics ( (ITRM) ) has shared an update.
On February 18, 2026, Iterum Therapeutics plc shareholders rejected four key proposals at an extraordinary general meeting, including an increase in authorized share capital, expanded directors’ authority to allot and issue securities, an opt-out from pre-emptive rights, and a reverse share split. The failure of these measures has significantly constrained the company’s ability to raise additional capital, leading management to warn that its operations, financial condition and ability to continue as a going concern are likely to be materially and adversely affected, increasing the likelihood of a wind-down, bankruptcy or similar proceeding and leaving shareholders facing a very high risk of little or no recovery, even as the company continues to explore strategic alternatives such as asset sales, licensing deals or other transactions under tight time and resource constraints.
The most recent analyst rating on (ITRM) stock is a Hold with a $0.31 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.
Spark’s Take on ITRM Stock
According to Spark, TipRanks’ AI Analyst, ITRM is a Neutral.
The score is held down primarily by weak financial fundamentals (minimal revenue, persistent losses, cash burn, and negative equity) and bearish technicals (price below major moving averages with negative MACD). The earnings call adds some support due to early launch traction and 2026 revenue guidance, but this is tempered by the need for additional capital, while the Nasdaq listing compliance issue adds further downside risk.
To see Spark’s full report on ITRM stock, click here.
More about Iterum Therapeutics
Iterum Therapeutics plc is a biopharmaceutical company focused on developing anti-infective therapies, with a particular emphasis on treatments for drug-resistant bacterial infections. The company operates in a capital-intensive segment of the healthcare sector and is reliant on continued access to equity financing and strategic transactions to fund its development programs and ongoing operations.
Average Trading Volume: 834,573
Technical Sentiment Signal: Sell
Current Market Cap: $14.52M
For an in-depth examination of ITRM stock, go to TipRanks’ Overview page.